NIAID Site Search

Nico Contreras, Ph.D., of University of Arizona, F31 sample application

Last Reviewed: March 31, 2025

Project Title: Role of neutrophil dysregulation and NET formation in complications of COVID-19 NIAMS Principal Investigator: Mariana J. Kaplan, M.D. Chief, Systemic Autoimmunity Branch, LCTU, NIAMS What is the role of neutrophils and NETs in the prognosis of and complications from COVID-19? Emerging evidence implicates neutrophils and neutrophil extracellular traps (NETs) in poorer outcomes and

Last Reviewed: May 26, 2020

The Vector Molecular Biology Section focuses on understanding how molecules from arthropod vectors are critical for the success of pathogen transmission and translating this knowledge into disease control opportunities.

Last Reviewed: September 27, 2022

A list of the core responsibilities of the NIAID Office of the Chief of Staff for the Immediate Office of the Director (IOD).

Last Reviewed: September 20, 2024

.

Published: October 16, 2024

An overview of the NIAID Laboratory of Immunoregulation including major areas of research.

Last Reviewed: December 4, 2024

In the BPARS, we apply a systems biology approach to understand selection dynamics and host-pathogen interactions in the context of defined genetic immunodeficiency diseases. This approach integrates genomics, transcriptomics (RNA-seq), and metabolomic methods to identify and characterize specializations that occur during within-host adaptation.

Last Reviewed: January 21, 2025

Antiretroviral therapy of pregnant women and antiretroviral treatment of infants have greatly reduced the rate of mother-to-child HIV transmission, also referred to as vertical transmission. Nevertheless, although these improved rates have occurred in some countries, vertical transmission rates remain relatively high in others. This may be due to multiple factors, including access to testing, care

Published: September 1, 2021

The objective of this study is to evaluate if the restoration of the vaginal microbiota to the infant at birth will restore the infant microbiome and decrease the risk of obesity and other immune-mediated diseases linked with Cesarean section (CS).

Apply for research support to study basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity.

Published: February 21, 2024

Regular, meaningful engagement with Tribal partners helps NIH ensure American Indians and Alaska Natives are well-represented in research and benefit from its outcomes.

Published: April 6, 2022

NIAID scientists developed tools to study evolution in enteroviruses���a virus group responsible for polio; hand, foot & mouth disease (HFMD); acute flaccid myelitis (AFM) & other diseases. Their findings may reveal pathways of viral evolution.

Published: December 10, 2024

Dr. Patricia D���Souza is Team Leader of the Clinical Laboratory Program in the Vaccine Clinical Research Branch of the Division of AIDS, NIAID. The Branch funds the HIV Vaccine Clinical Trials Network (HVTN). This is the largest international program for testing vaccines investigates ways to prevent infection with HIV, the virus that causes AIDS. As a Team Leader, I work to find with some of the

Last Reviewed: September 7, 2022

This program supports high throughput discovery and validation of novel B cell epitopes associated with infectious pathogens or vaccines against them, autoimmune diseases, allergens, or human leukocyte antigen epitopes associated with cell, organ, or tissue transplant rejection or tolerance.

Published: June 21, 2023

Sample grant summary statement from Mengxi Jiang, Ph.D., for NIH standard independent research project grant (R01).

Last Reviewed: January 25, 2023

Sample application from Timothy C. Fong, Ph.D., for Small Business Technology Transfer (STTR) grant.

Last Reviewed: November 29, 2022

NIH seeks research projects studying the ethical, legal, and social implications of human genetic or genomic research, including empirical qualitative and quantitative methods.

Published: December 20, 2023

Office of Research on Women’s Health and NIH Support for Research on Women’s Health Report of the Advisory Committee on Research on Women’s Health: Fiscal Years 2019–2020 508-compliant PDF

Last Reviewed: March 8, 2022

Science communication is rapidly evolving, and the growing use of preprints and the sheer number of published studies make it increasingly difficult to determine which findings are worthy of attention.

Published: September 20, 2023

Pivotal studies of some biomedical HIV and sexually transmitted infection (STI) prevention interventions have excluded cisgender women or demonstrated low efficacy among them, limiting their prevention options relative to other populations who experience high HIV and STI incidence. Findings show doxycycline postexposure prophylaxis (better known as DoxyPEP) did not prevent STI acquisition in cisgender women, despite showing promising results in gay, bisexual, and other men who have sex with men and transgender women in a previous study.

Published: December 20, 2023

On April 6, 2023, NIH postbac fellows participated in a seminar and discussion session led by Monica L. Wang, ScD, MS, a nationally recognized award-winning researcher and educator on health equity and science communication. Postbac Joanne Hunt recaps the insights shared about the rise and spread of scientific misinformation and actionable steps scientists can take to address this.

Published: May 1, 2023

The presence of antibodies that target one of the body���s own proteins was associated with severe infections that typically only occur when a person���s immune system is suppressed, based on a multi-cohort study of blood samples from more than 1,000 people. This study suggests autoimmune processes could be involved in the development of immunodeficiency in adulthood.

Published: May 31, 2024

The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor. Lenacapavir is administered every six months, making it the most durable HIV prevention method to have shown efficacy in this population

Published: June 26, 2024

Do you know some people who almost never get sick and bounce back quickly when they do, while other people frequently suffer from one illness or another? NIAID-supported researchers have pinpointed an attribute of the immune system called immune resilience that helps explain why some people live longer and healthier lives than others.

Published: June 13, 2023

The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a NIH report published today.

Published: May 22, 2020